Last reviewed · How we verify

NCT07342504: Project BEST

Better Experiences in Substance Treatment: A Brief Alcohol-focused Intervention Tailored for Patients in Opioid Agonist Treatment

Recruiting now NA Last updated 15 January 2026
What this trial tests

NA trial testing Brief opioid-informed alcohol treatment in Alcohol Use Disorder in 60 participants. Currently enrolling.

Timeline
21 January 2026
Primary endpoint
1 December 2026
1 March 2027

Quick facts

Lead sponsorUniversity of Notre Dame
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment60
Start date21 January 2026
Primary completion1 December 2026
Estimated completion1 March 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Notre Dame

Who can join

18 and older, any sex, with Alcohol Use Disorder or Opioid Use Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will help determine the feasibility and acceptability of a brief opioid-informed alcohol intervention in patients receiving prescribed buprenorphine for opioid use who are currently drinking alcohol. It will also provide initial information on whether the intervention improves outcomes related to alcohol use. The results of this proof-of-concept study will inform whether a future larger clinical trial is warranted.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Alcohol Use Disorder

Currently open trials in the same condition.

Other University of Notre Dame trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07342504.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing